KALA vs. HUGE, NRSN, FLGC, ORGS, BNTC, NERV, GLTO, TCRT, VBIV, and BIVI
Should you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include FSD Pharma (HUGE), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Orgenesis (ORGS), Benitec Biopharma (BNTC), Minerva Neurosciences (NERV), Galecto (GLTO), Alaunos Therapeutics (TCRT), VBI Vaccines (VBIV), and BioVie (BIVI). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
FSD Pharma's return on equity of -112.38% beat KALA BIO's return on equity.
KALA BIO received 297 more outperform votes than FSD Pharma when rated by MarketBeat users.
FSD Pharma has lower revenue, but higher earnings than KALA BIO. FSD Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
KALA BIO currently has a consensus price target of $18.00, suggesting a potential upside of 178.64%. Given KALA BIO's higher probable upside, equities research analysts plainly believe KALA BIO is more favorable than FSD Pharma.
In the previous week, FSD Pharma had 1 more articles in the media than KALA BIO. MarketBeat recorded 5 mentions for FSD Pharma and 4 mentions for KALA BIO. FSD Pharma's average media sentiment score of -0.18 beat KALA BIO's score of -0.19 indicating that FSD Pharma is being referred to more favorably in the news media.
KALA BIO has a beta of -1.85, meaning that its stock price is 285% less volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 1.2% of FSD Pharma shares are held by institutional investors. 13.4% of KALA BIO shares are held by insiders. Comparatively, 8.5% of FSD Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
KALA BIO beats FSD Pharma on 8 of the 14 factors compared between the two stocks.
Get KALA BIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KALA BIO Competitors List
Related Companies and Tools
